Table 1 Baseline characteristics.

From: HHLA2 is expressed in pancreatic and ampullary cancers and increased expression is associated with better post-surgical prognosis

Baseline characteristics

N = 194 (% or range)

Agea

 

67.9 (35.5–85.2)

Gender (male/female)

 

116 (59.8%)/78 (40.2%)

Positive marginsb

 

71 (36.6%)

Lymph nodes metastasis

 

119 (61.3%)

CA-19.9 (kU/l)a

 

73.0 (1–6556)

Differentiation

Well-differentiated

17 (8.8%)

 

Moderate

117 (60.3%)

 

Poor

60 (30.9%)

Origin (pancreas/ampulla)

 

122 (62.9%)/72 (37.1%)

T-stagec (pancreas/ampulla)

T1

20 (16.4%)/11 (15.3%)

 

T2

85 (69.7%)/18 (25.0%)

 

T3

17 (13.9%)/40 (55.6%)

 

T4

0 (0%)/3 (4.2%)

Adjuvant chemotherapy

 

71 (36.6%)

Systemic chemotherapyd

 

92 (47.4%)

Peri-operative draining

 

141 (72.7%)

Surgical Procedure

Whipple

139 (71.6%)

 

PPPD

40 (20.6%)

 

Distal pancreatectomy

15 (7.7%)

Recurrence

 

140 (72.2%)

Cancer-specific deathf

 

135 (69.6%)

  1. aMedian.
  2. bMargins ≤ 1 mm included as positive.
  3. cT-stage classification 8th edition (AJCC/UICC 2016).
  4. dAny systemic adjuvant of palliative chemotherapy.
  5. ePylorus-sparing pancreatico-duodenectomy.
  6. f8 patients died from causes other than pancreas or ampulary cancer (Cerebrovascular accident 3 × , myocardial infarction 2 × , multiple comorbidities 1 × , adjuvant chemo-radiation related 1 × , urothelial carcinoma 1 × ).
Back to article page